{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:28:57Z","timestamp":1761845337164},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Skin toxicity is a common, expected side effect of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) used for metastatic renal cell carcinoma (mRCC). We evaluated the association between skin toxicity and clinical efficacy outcomes of these agents in mRCC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Materials<\/jats:title><jats:p>Data were obtained from patients with mRCC treated with TKIs and\/or ICIs from 2016\u20132019 at a referral hospital in Mexico City. Clinical outcomes were compared among patients who developed treatment\u2010related cutaneous adverse events (AEs) and those without skin toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010five patients with mRCC were identified who were treated with sunitinib (51.4%), nivolumab plus cabozantinib (28.6%), nivolumab monotherapy (17.1%), or ipilimumab plus nivolumab plus cabozantinib (2.9%). Any grade skin toxicity was seen in 65.7% of patients. With a median follow\u2010up of 14\u00a0months, radiological responses were as follows: 48.6% stable disease, 25.7% partial response, and 2.8% complete response. Compared to subjects without skin toxicity, patients who developed cutaneous AEs had higher disease control rate 91.3% vs. 50.0% (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.019) and superior 12\u2010month overall survival rate 91% vs. 67% (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.01), respectively. There was a trend toward improved median progression\u2010free survival (16\u00a0months vs. 5\u00a0months, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.13). Grade 1\u20132 cutaneous toxicity was found to be predictive for disease control, with HR 2.72 (95% CI 1.1\u20136.71, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.030), and all grade cutaneous toxicity was prognostic of overall survival, with HR 0.18 (95% CI 0.04\u20130.91, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.039).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Cutaneous AEs are associated with improved overall survival and response in patients with mRCC treated with immunotherapy and\/or TKIs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.15583","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T11:42:45Z","timestamp":1618832565000},"page":"1242-1247","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor\u2010related cutaneous adverse events with outcomes in metastatic renal cell carcinoma"],"prefix":"10.1111","volume":"60","author":[{"given":"Eduardo","family":"Corona\u2010Rodarte","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n Mexico City Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Olivas\u2010Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n Mexico City Mexico"},{"name":"Department of Biostatistics University of Washington Seattle WA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuly A.","family":"Remolina\u2010Bonilla","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n Mexico City Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith G.","family":"Dom\u00ednguez\u2010Cherit","sequence":"additional","affiliation":[{"name":"Department of Dermatology Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n Mexico City Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine T.","family":"Lam","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Department of Medicine University of Colorado Anschutz Medical Campus Aurora CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n Mexico City Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"e_1_2_7_3_1","unstructured":"International Agency for Research on Cancer.Global Cancer Observatory: Cancer Today.2018."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066838"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.919"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5610-8"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12940"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds145"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2018_328"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0046"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.035"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30413-9"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0012"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.4296"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0335"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2010.12.007"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.03.003"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15583","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.15583","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:29:50Z","timestamp":1693294190000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.15583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/ijd.15583"],"URL":"https:\/\/doi.org\/10.1111\/ijd.15583","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"2020-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}